NUCLIDIUM AG

🎉 Announcing NUCLIDIUM AG representation at the 6th TRP Summit in Amsterdam, 3rd - 5th December 2024! 📢 Dr. Francesco De Rose, our Head of Pharmaceutical Development, will present a workshop on December 3rd titled 'Optimising Cu-61 Production and Safety for Next-Generation Radiopharmaceuticals.' Francesco will dive into: 💡 Developing streamlined processes to maximise Cu-61 yield and purity 💡 Establishing robust, automated radiolabeling protocols for seamless clinical translation 💡 Advancing safe and efficacious radiotracers with promising theranostic applications 🛠️ Ben Pais, MD our CMO, will lead an interactive session on 'Designing Optimal First in Human Radiopharmaceutical Trials for Translational Success: Regulatory Considerations. Join him to explore innovative strategies in trial design, dosimetry, and regulatory considerations for emerging radiopharmaceuticals. 🌟 Don’t miss this opportunity to engage with our experts and gain insights into the future of radiopharmaceutical innovation. Let’s connect and collaborate at the TRP Summit! #TRPSummit #Radiopharmaceuticals #TeamNuclidium #InnovationInOncology #Oncology #cancertherapeutics #pharma #radiotheranostic

We are excited to announce that the first patient has been imaged in a Phase 1 study evaluating our 61Cu-based radiotracer in patients with PSMA-positive prostate cancer. This is the first candidate from our broad theranostic pipeline to enter the clinic. 61Cu-NuriPro is the diagnostic component of our NuriPro program, binding specifically to Prostate Specific Membrane Antigen (PSMA). Upon successful completion of the trial we will advance our NuriPro program into a Phase 1/2 theranostic clinical trial, evaluating both the 61Cu-based imaging alongside the 67Cu-based therapeutic candidate. The non-randomized study is initiated by Gary Ulaner and is being conducted at Hoag Memorial Hospital Presbyterian in Newport Beach, California. It will evaluate the safety and effectiveness of our candidate compared to an 18F-based, FDA-approved PSMA-targeting radiotracer. 61Cu-NuriPro has the potential to overcome both detection and production challenges of currently available agents. It enables delayed imaging, allowing for the detection of even the smallest metastases. With a 3.3-hour half-life, compared to the 1-to-2-hour half-life of most molecular imaging agents, it allows for a far greater distribution range following production. In addition, it can be easily manufactured at room temperature, enabling on-demand preparation and a simplified and easy-to-apply workflow with reduced need for laboratory equipment. #CancerCare #CancerDiagnostics #Prostatecancer #MedicalImaging #PrecisionOncology #Radiopharmaceuticals #Radiotheranostics #Theranostics

We would like to thank Pro Concept Unternehmensberatung and TV Oberfranken for their supportive reporting and of course for the strong cooperation with LinaThera on our joint project of cancer therapy with copper isotopes! Wir möchten uns recht herzlich für die unterstützende Berichtserstattung bei Pro Concept Unternehmensberatung sowie bei TV Oberfranken bedanken. Zudem bei unserem Partner LinaThera für die starke Zusammenarbeit in dem gemeinsamen Projekt der Krebstherapie mit Kupferisotopen!

Together with LinaThera and Dr Christoph Thiel, our CEO Dr Leila Jaafar recently visited the Medical Valley EMN e. V. in Forchheim for an inspiring event on innovative companies in the region. We had the honor of meeting Hallerndorf's mayor Gerhard Bauer, the Bavarian Minister of Economic Affairs Hubert Aiwanger and the Minister of State for the Environment and Consumer Protection Thorsten Glauber. We are grateful for the opportunity to contribute to the fight against cancer and for the support of our collaborative project with LinaThera. Catch the full TV report here: https://lnkd.in/dGVNAfE8 Zusammen mit LinaThera und Dr. Christoph Thiel hat unsere Geschäftsführerin Dr. Leila Jaafar erneut das Medical Valley EMN e. V. in Forchheim zu einer innovativen Veranstaltung besucht. Dabei waren unter anderem Hallerndorfs Bürgermeister Gerhard Bauer, der bayrische Wirtschaftsminister Hubert Aiwanger und der Staatsminister für Umwelt und Verbraucherschutz Thorsten Glauber. Wir bedanken uns recht herzlich für die Möglichkeit, unseren Beitrag zur Krebsbekämpfung leisten zu können, und für die Unterstützung des gemeinsamen Projekts mit LinaThera. Zum TV Oberfranken Bericht: https://lnkd.in/dGVNAfE8

NUCLIDIUM is partnering with Guerbet! As a long-standing expert in the field of diagnostic imaging, Guerbet has a wealth of knowledge and an extensive network in diagnostic imaging, manufacturing, and clinical trials. We will draw on these valuable resources to reach our goal of accelerating the development of our pipeline towards clinical proof-of-concept and ensuring reliable supply chains for copper-based radiopharmaceuticals. Looking forward to our collaboration and to gaining strategic insights from Francois Nicolas and his team at Guerbet! #CancerCare #CancerDiagnostics #MedicalImaging #PrecisionOncology #Radiopharmaceuticals #Radiotheranostics #Theranostics

🎉 Congratulations to our collaboration partner LinaThera as a winner of the business plan competition Nordbayern 2024, phase 2. 🎉

⚡ Exciting developments at Nuclidium as we prepare for LSX - partnering for Life Science eXecutives! ⚡ Investments by industry giants like Lilly and BMS highlight the potential and competitive nature of the radiopharmaceutical sector. Here’s why you should meet with Leila Jaafar and Andreas Schuh on the 29th and 30th of April in London: ✅ Innovative Theranostics: Our Cu-61 and Cu-67 pairs offer precise diagnosis and targeted treatment, improving efficacy and minimizing side effects for major cancers such as breast, prostate, lung, and pancreatic. ✅ Advanced Diagnostics: Cu-61’s longer half-life and superior properties simplify manufacturing and extend usability, enhancing diagnostic applications. ✅ Effective Therapeutics: Cu-67 aligns perfectly with our targeting molecules, allowing for higher tumor dosage with reduced toxicity and shorter hospital stays. ✅ Sustainable Production: In collaboration with LinaThera, our proprietary, scalable production facilities are independent of nuclear reactors, beginning in Germany with plans for global expansion. With commitments secured and a strategic investor on board, we're gearing to close Series A2 in Q3. Join us at LSX - partnering for Life Science eXecutives to discover how our cutting-edge solutions are poised to revolutionize cancer treatment. #LSX #Radiopharmaceuticals #InvestInInnovation #LinaThera #Nuclidium

⚡ Exciting developments at Nuclidium as we prepare for LSX - partnering for Life Science eXecutives! ⚡ Investments by industry giants like Lilly and BMS highlight the potential and competitive nature of the radiopharmaceutical sector. Here’s why you should meet with Leila Jaafar and Andreas Schuh on the 29th and 30th of April in London: ✅ Innovative Theranostics: Our Cu-61 and Cu-67 pairs offer precise diagnosis and targeted treatment, improving efficacy and minimizing side effects for major cancers such as breast, prostate, lung, and pancreatic. ✅ Advanced Diagnostics: Cu-61’s longer half-life and superior properties simplify manufacturing and extend usability, enhancing diagnostic applications. ✅ Effective Therapeutics: Cu-67 aligns perfectly with our targeting molecules, allowing for higher tumor dosage with reduced toxicity and shorter hospital stays. ✅ Sustainable Production: In collaboration with LinaThera, our proprietary, scalable production facilities are independent of nuclear reactors, beginning in Germany with plans for global expansion. With commitments secured and a strategic investor on board, we're gearing to close Series A2 in Q3. Join us at LSX - partnering for Life Science eXecutives to discover how our cutting-edge solutions are poised to revolutionize cancer treatment. #LSX #Radiopharmaceuticals #InvestInInnovation #LinaThera #Nuclidium

Check out GE HealthCare’s video series on radiopharmaceuticals ahead of #SNMMI2024, featuring our CEO, Leila Jaafar. Leila explains the versatile potential of radioisotopes in oncology and beyond, as well as the impact of radiometals on the future of nuclear medicine: https://lnkd.in/d87cZ_fc #CancerCare #PrecisionOncology #Radiopharmaceuticals #Radiotheranostics #Theranostics

💡 Unlocking PET Tracer Potential with Copper-61 at ESRR 2024 in Coimbra, April 18-21 💡 Copper-61 is a highly desirable radionuclide for labeling #PET tracers in pre-clinical and clinical settings. It has a half-life of 3.33 hours and is a favorable positron emitter (61% β+, Emax = 1.216 MeV). Its moderate 3.33-hour half-life offers an advantage over existing clinical tracers, enabling PET scans at extended post-injection intervals. At #ESRR24, Dr. Markus Baier and Dr. Nicole Schubert will showcase a method for producing [61Cu]CuCl2, a #radiopharmaceutical precursor with exceptional specificity, #radionuclide purity, and yield. Furthermore, we'll present the synthesis of [61Cu]Cu-NuriPro, a PSMA-targeting PET radiotracer, highlighting its first successful application.   Join us on our journey, we would love to collaborate with you! For more information, contact us at info@nuclidium.com